



www.MedChemExpress.com

Inhibitors, Screening Libraries, Proteins

MAPKAPK2 (MK2)

Mitogen-activated protein kinase activated protein kinase 2; MAP kinase activated protein kinase 2; MAPK activated protein kinase 2; MAPKAP kinase 2

MAP kinase-activated protein kinase 2 (MAPKAPK2) is an enzyme that in humans is encoded by the MAPKAPK2 gene. MAPKAP kinase-2 (MK2) is originally identified by its phosphorylation of glycogen synthase at serine-7 and the corresponding serine in a peptide (GS peptide-1) modelled after the N-terminus of glycogen synthase.


MAPKAP kinase-2 is a novel protein kinase activated by mitogen-activated protein kinase. This MAP kinase activated protein kinase, termed MAPKAP kinase-2, is distinguished from S6 kinase-II (MAPKAP kinase-1) by its response to inhibitors, lack of phosphorylation of S6 peptides and amino acid sequence.

MAPKAPK2 (MK2) Inhibitors

CC-99677

Cat. No.: HY-139504

CC-99677 is a potent, covalent, and irreversible inhibitor of the mitogen-activated protein (MAP) kinase-activated protein kinase-2 (MK2) pathway in both biochemical (IC_{50} =156.3 nM) and cell based assays (EC_{50} =89 nM). CC-99677 is extracted from patent WO2020236636, compound 1.




Purity: 98.02%
Clinical Data: Phase 2
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MK2-IN-1

Cat. No.: HY-12834

MK2-IN-1 is a potent and selective MAPKAPK2(MK2) inhibitor(IC_{50} =0.11 μ M) with a non-ATP competitive binding mode.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

MK2-IN-3

Cat. No.: HY-131249

MK2-IN-3 is a potent and selective inhibitor of MAPKAP-K2 (MK-2), with an IC_{50} of 8.5 nM. MK2-IN-3 shows selectivity for MK-2 over MK-3, MK-5, ERK2, MNK1, p38a (IC_{50} s=0.21, 0.081, 3.44, 5.7, and >100 μ M, respectively) and MSK1, MSK2, CDK2, JNK2, IKK2 (IC_{50} s>200 μ M).



Purity: 98.21%
Clinical Data: No Development Reported
Size: 10 mM \times 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MMI-0100

Cat. No.: HY-P3412

MMI-0100 is a cell-permeant peptide inhibitor of mitogen activated protein kinase activated protein kinase II (MK2). MMI-0100 reduces intimal hyperplasia ex vivo and in vivo. MMI-0100 suppresses IL-6 expression without effect on IL-8 expression.


YARAAARQARAKALARQLGVAA

Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg

RMM-46

Cat. No.: HY-116533

RMM-46 is a selective and reversible covalent inhibitor for MSK/RSK-family kinases.




Purity: >98%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

CMPD1

Cat. No.: HY-108643

CMPD1 is a selective and non-ATP-competitive p38 MAPK-mediated MK2 phosphorylation inhibitor with apparent K_i (K_i^{app}) of 330nM.




Purity: 99.45%
Clinical Data: No Development Reported
Size: 10 mM \times 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MK2-IN-1 hydrochloride

Cat. No.: HY-12834A

MK2-IN-1 hydrochloride is a potent and selective MAPKAPK2(MK2) inhibitor(IC_{50} =0.11 μ M) with a non-ATP competitive binding mode.




Purity: 98.96%
Clinical Data: No Development Reported
Size: 10 mM \times 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

MK2-IN-3 hydrate

Cat. No.: HY-112457

MK2-IN-3 hydrate (compound 16) is an orally active, selective, and ATP-competitive MAPKAP-K2 (MK-2) inhibitor with an IC_{50} of 0.85 nM.




Purity: \geq 99.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg

PF-3644022

Cat. No.: HY-107427

PF-3644022 is a potent, selective, orally active and ATP-competitive MAPKAPK2 (MK2) inhibitor with an IC_{50} of 5.2 nM and a K_i of 3 nM. PF-3644022 also inhibits MK3 and p38 regulated/activated kinase (PRAK) with IC_{50} s of 53 nM and 5.0 nM, respectively.




Purity: 99.93%
Clinical Data: No Development Reported
Size: 10 mM \times 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Zunsemetinib

(ATI-450; CDD-450)

Cat. No.: HY-139553

Zunsemetinib (CDD-450) is an orally active and selective p38 α mitogen-activated protein kinase-activated protein kinase 2 (MK2) pathway inhibitor. Zunsemetinib can be used for the research of immuno-inflammatory diseases.



Purity: 99.37%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg